Confronto
Mazdutide vs. Petrelintide
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Metabolico
Metabolico
N. CAS
2259884-03-0
nessun dato
Peso molecolare
4790 g/mol
nessun dato
Emivita
132 h
nessun dato
Sequenza
synthetisches Oxyntomodulin-Analogon (39 Aminosäuren) mit Fettsäureseitenkettenessun dato
Meccanismo d'azione
Mazdutide
Mazdutide is a dual agonist at the GLP-1 and glucagon receptors and is structurally derived from the gut hormone oxyntomodulin. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at elevated blood glucose, and modulation of appetite and gastric emptying. The glucagon component can influence energy expenditure and hepatic lipid and glucose metabolism. A fatty-acid side chain enables albumin binding and the weekly administration interval.
Petrelintide
As an amylin analogue, petrelintide acts through amylin receptors, promoting satiety and slowed gastric emptying — a satiety pathway independent of the GLP-1 axis.
Base di evidenze
Evidenza più alta
RCT sull'uomo
RCT sull'uomo
Studi
4
1
di cui sull'uomo
4
1
Effetti registrati
4
2
Contraddizioni aperte
0
0
Eventi avversi documentati
0
1
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Mazdutide and Petrelintide?
- Mazdutide is classified as "Metabolico", while Petrelintide is classified as "Metabolico". Mazdutide: Synthetic oxyntomodulin analogue that simultaneously activates the GLP-1 and glucagon receptors (dual agonist). Developed by Innovent Biologics and Eli Lilly. In China the NMPA approved mazdutide on 27 June 2025 for chronic weight management; a further filing for type 2 diabetes is under review in China. Outside China the substance remains in clinical development. Petrelintide: Petrelintide is a long-acting amylin analogue (Zealand Pharma, with Roche) for once-weekly subcutaneous use — developed for weight management with a focus on strong tolerability. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Mazdutide or Petrelintide?
- The highest available evidence level is "RCT sull'uomo" for Mazdutide and "RCT sull'uomo" for Petrelintide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Mazdutide and Petrelintide in Germany and the United States?
- Germania: Mazdutide — Solo ricerca, Petrelintide — Non approvato. Stati Uniti: Mazdutide — Solo ricerca, Petrelintide — Non approvato. These are factual summaries with source and review date on the individual pages.